FMI analysis suggests that the allergy clinical trial services market will shift from traditional research methodologies toward highly specialized, biomarker-driven platforms. The research report highlights that this transformation is driven by increasing demand for advanced allergy therapeutics across indications such as allergic rhinitis, asthma, and food allergies.